Abstract
Whilst intracranial neuromodulation therapies (such as deep brain stimulation (DBS) and responsive neurostimulation (RNS)) are already well-established in adult practice, there has only recently been an accelerated interest in these to treat children with drug-resistant neurological diseases - in particular, epilepsy and movement disorders such as dystonia. There is a well-respected doctrine in pediatric medicine that ‘children are not small adults’ and should not be treated as such. This stance should hold true just as much for the design of medical devices, including those delivering intracranial neuromodulation to treat children with neurological disorders.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Neuromodulation: Technology at the Neural Interface
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
